United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	April 2009
Publisher	Business Monitor
Product Type	Report
Pages	106
ISBN Number	not applicable
Product Code	BMI03696

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$416 | €280

FAX Order above formats by FAX

Summary

The United Arab Emirates (UAE) has retained its pole position in BMI's Q209 Business Environment Rankings for the 17 key markets within the Middle East and Africa (MEA) region. Globally, the UAE is ranked eighteenth, and is thus comparable to some developed European markets. This high ranking illustrates its capacity to compete with mature markets in terms of the attractiveness of the business environment, especially given UAE's forecast compound annual growth rate (CAGR) of 9.97% through to 2013. By the end of the forecast period, the market is expected to be valued at AED5.04bn (US$1.37bn) at consumer prices, increasing from AED3.42bn (US$0.85bn) in 2008. Unfavourable fluctuation in the exchange rate of the dirham against the euro already resulted in an increase in drug expenditure during late 2008, which is likely to result in the authorities looking to import cheaper generics and/or to boost local production.

Generally speaking, key drivers of overall market growth will remain the Emirates' wealthy and urban population, strong preference for branded drugs, rising demand for chronic and long-term diseases treatment and continued investment in health infrastructure. Additionally, the opening of the first pharmacy in a grocery retail store in February 2009 by local pharmacy chain BinSina, on behalf of the global retailer Carrefour, should set the trend for future development of UAE's over-the-counter (OTC) medicines market, which presently accounts for 17% of the overall market. Over the period 2009-13, OTCs are forcast to post a CAGR of 10.59%, to reach AED912mn (US$248mn) at consumer prices.

Indeed, the opening of the hypermarket pharmacy indicates the Ministry of Health's willingness to encourage improvements of the healthcare sector through innovative solutions.

The government is making concerted efforts to crack down on the trade of counterfeit medicines. Plans unveiled in February 2009 seek to boost the number of customs inspectors and portable drug detectors, especially in the super-busy port of Dubai. By June 2009, unregistered pharmaceutical and healthcare products - as the recent addition of well medical devices and nutritional supplements to the list - will not be permitted to enter or pass through the UAE. In a related development, Tawan Hospital became the first healthcare institution in the Emirates to launch a patient safety programme. The changes also complement the Federal Medical Liability Law, which stipulates that all health professionals - including complementary and alternative medicine (CAM) practitioners - must be insured against medical.

In a worrying development, in January 2009, the UAE dramatically altered laws concerning research and development to prevent human cloning, while also further regulating fertility treatments with regard to implantation and abortion. BMI cautions that, while ethical concerns must be considered, the impact of this law may hinder the development of life sciences in the country, which now includes major global biotechnology players such as Amgen and Genzyne. On the other hand, the government is aiming to rectify the presently unnatural sex distribution, with the population consisting of more than twice as many males as females.

Content

Executive Summary
United Arab Emirates Pharmaceuticals And Healthcare Industry SWOT
United Arab Emirates Political SWOT
United Arab Emirates Economic SWOT
United Arab Emirates Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
UAE - Market Summary
Regulatory Environment
Recent Regulatory Developments
Pharmaceutical Advertising
Intellectual Property Regime
Counterfeit Medicines
Pricing And Reimbursement Regime
Price Cuts
Recent Pricing And Reimbursement Developments
Regional Harmonisation
Free Trade Agreements
Industry Trends and Developments
Epidemiology
Healthcare Sector
Healthcare Funding
Healthcare Sector Reforms
Recent Healthcare Sector Developments
Hospital Sector Developments
Health Insurance
Expatriate Worker Insurance
Recent Health Insurance Industry Developments
Health Tourism
Prescribing Practices
Domestic Pharmaceutical Sector
Foreign Companies
Company Developments
Pharmaceutical Distribution and Retail
Recent Developments in Pharmaceutical Distribution and Retail
Research and Development
DuBiotech
Complementary and Traditional Medicine
Medical Devices
Recent Developments in the Medical Devices Market
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Macroeconomic Scenario
Growth Outlook Weakening
Prescription Market Forecasts
Patented Market Forecasts
Patented Market Forecasts
Generics Market Forecast
OTC Market Forecast
Pharmaceutical Trade Forecasts
Pharmaceutical Trade Forecasts
Medical Devices
Other Healthcare Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Leading Foreign Companies
GlaxoSmithKline
Pfizer
Novartis
Johnson & Johnson (J&J)
Sanofi-Aventis
Abbott Laboratories
Merck & Co
Indigenous Manufacturers
Gulf Pharmaceutical Industries (Julphar)
Globalpharma
Modern Pharmaceutical Company (MPC)
NeoPharma
Country Snapshot: UAE Demographic Data
Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q209
- Table: Profit Margins For Medicines In The UAE
- Table: DHA Healthcarre System Implementation Timeline
- Table: National Health Insurance Company - Available Plans
- Table: Incentives For Companies To Move To DuBiotech
- Table: UAE - Drug Expenditure Indicators, Historical Data and Forecasts
- Table: UAE - Health Expenditure Indicators, Historical Data and Forecasts
- Table: United Arab Emirates - Economic Activity
- Table: UAE - Prescription Market Indicators, Historical Data and Forecasts (AEDmn unless otherwise stated)
- Table: UAE - Patented Drug Market Indicators, Historical Data and Forecasts
- Table: UAE- Generics Drug Market Indicators, Historical Data and Forecasts
- Table: UAE - OTC Drug Market Indicators, Historical Data and Forecasts (AEDmn unless otherwise stated)
- Table: UAE - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
- Table: UAE - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
- Table: UAE - Other Healthcare Indicators, Historical Data and Forecasts
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators, 2000-2004
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted